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Abstract
Objective: Rectal microbicides are needed to reduce the risk of HIV acquisition associated with unprotected receptive anal
intercourse. The MTN-007 study was designed to assess the safety (general and mucosal), adherence, and acceptability of a
new reduced glycerin formulation of tenofovir 1% gel.
Methods: Participants were randomized 1:1:1:1 to receive the reduced glycerin formulation of tenofovir 1% gel, a
hydroxyethyl cellulose placebo gel, a 2% nonoxynol-9 gel, or no treatment. Each gel was administered as a single dose
followed by 7 daily doses. Mucosal safety evaluation included histology, fecal calprotectin, epithelial sloughing, cytokine
expression (mRNA and protein), microarrays, flow cytometry of mucosal T cell phenotype, and rectal microflora.
Acceptability and adherence were determined by computer-administered questionnaires and interactive telephone
response, respectively.
Results: Sixty-five participants (45 men and 20 women) were recruited into the study. There were no significant differences
between the numbers of $ Grade 2 adverse events across the arms of the study. Likelihood of future product use
(acceptability) was 87% (reduced glycerin formulation of tenofovir 1% gel), 93% (hydroxyethyl cellulose placebo gel), and
63% (nonoxynol-9 gel). Fecal calprotectin, rectal microflora, and epithelial sloughing did not differ by treatment arms during
the study. Suggestive evidence of differences was seen in histology, mucosal gene expression, protein expression, and T cell
phenotype. These changes were mostly confined to comparisons between the nonoxynol-9 gel and other study arms.
Conclusions: The reduced glycerin formulation of tenofovir 1% gel was safe and well tolerated rectally and should be
advanced to Phase 2 development.
Trial Registration: ClinicalTrials.gov NCT01232803.
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Introduction
Rectal microbicides (RM) are currently being developed to
prevent or at least significantly reduce the risk of HIV acquisition
associated with unprotected receptive anal intercourse (RAI) [1].
RAI is a common sexual practice among men who have sex with
men (MSM) [2]. Recent epidemiological data have suggested that
RAI is also common among men and women in the developed and
developing world [3–6]. As a consequence there is an urgent need
to develop a safe and effective RM. Attention is currently focused
on the development of tenofovir (TFV) gel as a potential RM. The
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vaginal formulation of TFV that was used in the CAPRISA 004
study [7] has been evaluated in a Phase 1 rectal safety study
(RMP-02/MTN-006) [8]. Use of the gel was associated with mild
to moderate gastrointestinal symptoms including bloating, pain,
urgency, and diarrhea. The vaginal formulation of TFV is
hyperosmolar (3111 mOsmol/kg) and it is possible that these
symptoms were linked to product osmolality [9]. Consequently,
the TFV used in the MTN-007 study was formulated with a lower
glycerin concentration (5% w/w mg rather than the 20% w/w in
the vaginal formulation) that results in a product osmolality of 836
mOsmol/kg [10]. It was anticipated this formulation would be
better tolerated by study participants.
In the two phase 1 trials of antiretroviral rectal microbicides
conducted to date, product use was not associated with any
significant change in mucosal safety parameters [8,11]. Whilst this
is reassuring, the possibility exists that the range of parameters
used in these studies was too narrow and might have missed
unanticipated or subtle but important mucosal changes. To
mitigate this situation, the MTN-007 study included microarray
assessment of mucosal gene expression. In addition, a nonoxynol-9
(N-9) arm was included to help determine the utility of individual
mucosal safety assays in detecting mucosal injury. Rectal use of N-
9 in humans has been associated with transient mild gastrointes-
tinal discomfort as well as minor histological abnormality [12] and
has been associated with induction of proinflammatory responses
in cervical epithelial cells [13]. It was hoped that these additional
assessments would help provide a more comprehensive assessment
of mucosal safety.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
The study was designed by the investigators with collaborative
input from CONRAD and the NIAID/DAIDS/Prevention
Sciences Integrated Preclinical-Clinical Program (IPCP) for HIV
Topical Microbicides, as stipulated in the award notice and
reviewed by the U.S. Food and Drug Administration (FDA). The
study was approved by the University of Pittsburgh Institutional
Review Board (IRB) as well as the University of Alabama IRB and
the Fenway Health IRB. All subjects provided written informed
consent. The trial is registered at ClinicalTrials.gov, number
#NCT01232803 and is in compliance with the CONSORT 2010
recommendations for reporting of trial results (www.consort-
statement.org) [14,15].
Study Schema
The primary objective of MTN-007 was to evaluate the safety of
TFV gel when applied rectally. Secondary objectives included
evaluation of the acceptability of TFV gel, the safety of the
hydroxyethyl cellulose (HEC) placebo gel, and determining
whether the use of either TFV or N-9 gels was associated with
rectal mucosal damage. MTN-007 was a Phase 1, double blind,
placebo-controlled trial in which participants were randomized to
receive rectal TFV, N-9, HEC gels or No Rx (1:1:1:1) at three
clinical sites (Pittsburgh, PA; Birmingham, AL; and Boston, MA).
The study protocol was approved by IRBs at all three sites and
informed consent was received from all participants. Enrollment
began in October 2010 and the last participant completed the
study in July 2011. The target sample size is 60, equally split to 15
in each arm, which ensures a 79% probability to observe at least
one Grade 2 or higher adverse event in an arm when the true
event rate is 10%. Five additional enrollees were recruited to
preserve the study power in the case of participants using less than
5 doses in the 7-day dosing period or fail to complete the final
clinical visit. A blinded statistician from The Statistical Center for
HIV/AIDS Research & Prevention (SCHARP), University of
Washington, Seattle, WAS, USA created lists containing randomly
generated unique three-digit codes for study product randomiza-
tion for each clinical site. Participants, study staff, pharmacists,
clinicians and statisticians were blinded to study assignments.
Study Population
The study population consisted of healthy, RAI-abstinent, HIV-
uninfected, adults (male and female) aged 18 or older at time of
screening. Female participants were required to be using an
acceptable form of contraception (e.g., barrier method, intra
uterine device, hormonal contraception, surgical sterilization, or
vasectomization of the male partner). Individuals with abnormal-
ities of the colorectal mucosa, significant gastrointestinal symptoms
(such as a history of rectal bleeding), evidence of anorectal
Chlamydia trachomatis (CT) or Neisseria gonorrhea (GC) infection,
chronic hepatitis B infection, or a requirement to use drugs that
were likely to increase the risk of bleeding following mucosal
biopsy were excluded from the study.
Study Products
Reduced glycerin (RG)-TFV 1% gel was supplied by CON-
RAD (Arlington, VA, USA). 2% N-9 was provided as Gynol IIH
(Johnson & Johnson, Fort Washington, PA). HEC gel, known as
the ‘‘Universal Placebo Gel’’ [16], and used in a previous Phase 1
rectal safety study of the UC781 gel [11], was also supplied by
CONRAD (Arlington, VA, USA). Each participant was assigned a
carton of applicators, based on the randomization number. At the
Treatment 1 Visit the participant’s first dose of study product was
administered by the clinic staff. During the period of daily
administration study participants were instructed to insert one
dose of gel into the rectum once daily throughout the 7-day period.
Rectal administration of study product occurred in the evening or
before the longest period of rest. All study products were provided
in identical opaque HTI polypropylene pre-filled applicators (HTI
Plastics, Lincoln, NE) containing 4 mL of study product.
Study Procedures
There were a total of five study visits and two follow-up phone
calls. After obtaining informed consent all participants were
screened with a thorough medical history, a targeted physical
examination, a digital rectal examination, and collection of swabs
for CT/GC nucleic acid amplification testing (NAAT). Urine was
also collected for CT/GC NAAT and for pregnancy testing in the
female participants (pregnancy testing was repeated at all
subsequent clinical visits). Blood was collected for safety labs
(complete blood count, urea nitrogen, creatinine, alanine amino-
transferase, and aspartate aminotransferase) and serology (syphilis,
HIV-1, hepatitis B, and herpes simplex 1 and 2). Participants who
met the inclusion and exclusion criteria during the Screening Visit
proceeded to an Enrollment Visit. At the Enrollment Visit
participants were randomized, a behavioral questionnaire was
administered and a rectal examination and a focused physical
examination were performed. Swabs were collected for assessment
of rectal microflora and quantification of cytokines/chemokines in
rectal secretions. Participants then received a Normosol-R pH 7.4
enema and effluent was collected for evidence of epithelial
sloughing and a sample of feces collected for measurement of
fecal calprotectin. A flexible sigmoidoscope was then inserted into
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the rectum and 7 biopsies were collected at 15 cm from the anal
margin. A disposable anoscope was inserted into the anal canal
and high resolution anoscopy (HRA) of the anorectum was
performed at 166magnification with collection of 7 rectal biopsies
at 9 cm from the anal margin. Biopsies were used for histology,
qRT-PCR, microarray analysis, and flow cytometry. At the
Treatment 1 Visit (performed within 7–28 days of the Enrollment
visit), all participants randomized to receive gel product had a
single applicator of study gel inserted into the rectum. Within 30
minutes, swabs were collected for microflora and cytokines. An
enema was administered and the same rectal samples, including
biopsies, were collected as occurred during the Enrollment Visit.
At the Treatment 2 Visit (performed at least 7 days after
Treatment Visit 1) participants randomized to receive gel product
were provided with 7 applicators of study product to take home
and asked to insert the contents of one applicator daily for 7 days.
The Final Clinic Visit occurred no more than 21 days after
Treatment Visit 2 and was identical to the Enrollment Visit except
that anogenital testing (CT/GC) was only performed if clinically
indicated.
Clinical Safety and Laboratory Assessments
Emergent adverse events (AEs) were graded using the Division
of AIDS Table for Grading the Severity of Adult and Pediatric
Adverse Events, Version 1.0, December 2004 as well as
Addendum 1 and 3 (Female Genital and Rectal Grading Table for Use
in Microbicide Studies (http://rsc.tech-res.com/
safetyandpharmacovigilance/). In cases where an AE was covered
in both tables, the Female Genital or Rectal Grading Table for Use in
Microbicide Studies was the grading scale utilized.
Product Acceptability
Overall product like (or dislike) and likelihood of gel use in the
future were assessed using an internet based computer assisted self-
interview (CASI). To monitor adherence, participants were asked
to use a phone reporting system after each episode of gel use.
Mucosal Safety
Histology. A qualitative scoring system developed for inflam-
matory bowel disease (IBD) research [17] and adapted for use in
rectal microbicide trials [18] was used to characterize potential
product associated injury with a scale of 1 (normal) to 5 (mucosal
erosion or ulceration).
Fecal calprotectin. Fecal calprotectin was measured using a
commercial assay (Genova Diagnostics, Asheville, NC, USA) [19].
Epithelial sloughing. Epithelial sloughing was evaluated
using a modification of a previously described technique [20].
Briefly, lavage fluid, collected following the Normosol enema was
spun at 1000 rpm for 5 minutes. The cell pellet was resuspended
in 1 mL of 2% paraformaldehyde. The suspension was placed in a
petri dish that had previously been marked with quadrants. Each
quadrant of the petri dish was scanned with a dissecting
microscope at a magnification of 406. The total number of
.2 mm epithelial sheets in each quadrant of the petri dish were
recorded.
Rectal microflora. Rectal microflora were characterized
using previously described semi-quantitative culture analysis
techniques [21,22] that have been used in other rectal microbicide
Phase 1 studies [8,11].
Mucosal T cell phenotype. Mucosal mononuclear cells were
isolated from rectal biopsies using a combination of mechanical
and enzyme digestion as previously described [11]. Flow
cytometric analysis was performed on a BDTM LSRFortessa
cytometer (BD Biosciences, San Jose, CA). All data were stored in
list mode and analyzed with BDTM FACSDIVA operating system
and Flow Jo (Tree Star, Inc., Ashland, OR). All antibodies were
purchased from BD Biosciences, San Jose, CA (PerCP-CD45,
Clone 2D1; Pacific Blue-CD3, Clone UCHT1; PE-Cy7-CD4,
Clone SK3; APC-H7-CD8, Clone SK1; FITC-CD69, Clone
FN50; APC-CD184 (CXCR4), Clone 12G5 and PE-CD195
(CCR5)) and titrated under assay conditions to determine an
optimum saturating dilution. Cells were first stained with LIVE/
DEADH Fixable Aqua stain fluorescence (Life Technologies,
Eugene, OR).
Cytokine and chemokine mRNA expression. Rectal
biopsies were homogenized in the presence of 0.5 mm RNase-
free zirconium beads with the aid of a Bullet Blender homogenizer
(Next Advance Inc., Averil Park, NY). RNA was then purified on
columns using an RNAqueousH-4PCR kit (Applied Biosystems/
Ambion, Foster City, CA). The extracted total RNA was eluted in
a volume of 100 ml and DNase 1- treated. 1000 ng of total RNA
from biopsy samples were converted to cDNA using Multi-
ScribeTM reverse transcriptase and TaqManH Reverse Transcrip-
tion reagents (Applied Biosystems, Roche Molecular Systems, Inc.,
Branchburg, NJ). Oligo dT(20) was used to prime the reverse
transcription (RT) reaction and reactions were run on the Applied
Biosystems VeritiTM Dx Thermal Cycler (Life Technologies
Corporation, Carlsbad, CA). Three reference genes (GAPDH,
b-actin, and b2 Microglobulin b2M) were used to normalize
mucosal gene expression of CD45, IL-1b, IL-6, IL-12p40, IL-8,
IL-17, IFN-c, MIP-1a, MIP-1b, TNF-a, IL23, CCR5 and
RANTES (Table S1). All qRT-PCR experiments were performed
on a Bio-Rad CFX96 Real Time PCR System (Bio-Rad,
Hercules, CA).
Luminex analysis of rectal secretions. LuminexH was
used to measure IFN-c, IL-1b, IL-6, IL-8, IL-12 (p40), IL-17,
MIP-1a, MIP-1b, RANTES and TNF-a in rectal secretions
(MILLIPLEX MAP kit; Millipore, Billerica, MA).
Microarray analysis. RNA was extracted from colorectal
biopsies taken from 32 male study participants (8 men per study
arm, including the no-treatment arm) using the RNeasy Mini Kit
(Qiagen, Valencia, CA). 200 ng of total RNA was amplified and
labeled using the Illumina TotalPrep RNA Amplification kit
(Ambion, Grand Island NY). cRNA was hybridized to Hu-
manHT12 v4 Expression BeadChips (Illumina Inc., San Diego,
CA).
Analysis of Outcomes
Adverse events were evaluated for the full study cohort that
included all participants that were randomized into the study. All
adverse events were classified using the MedDRA organ system
class/preferred term. The proportion of participants having at
least one AE event was compared across arms using the Chi
Square test or Fisher’s exact test when counts are small. Product
acceptability was determined through a CASI interview and was
operationalized as intentionality of product use with RAI having a
rating in the upper one third of a 10-point Likert scale (values of 7–
10). Histology, fecal calprotectin, epithelial sloughing, rectal
microflora, and mucosal biomarkers were summarized for each
arm by mean and standard deviation among participants who
completed at least 5 doses of gels during the 7-day product use
period and completed the Final Clinic Visit. Using linear
regression, pairwise group comparisons were conducted across
groups after adjustment for baseline variability for biomarkers
measured after the single-dose use and for the 7-day use,
separately. Multiple testing in mucosal biomarkers was adjusted
for by using Bonferroni correction to control family wise error
rate, as well as using the Benjamini-Hochberg procedure to
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control false discovery rate (FDR) [23]. Microarray data were pre-
processed using robust spline normalization and variance stabiliz-
ing transformation. Unexpressed or low variability probes were
filtered out, leaving 1928 probes for analysis of treatment effects
versus control using a Bayesian statistical framework Cyber-T and
Benjamini-Hochberg false discovery rate (FDR) significance
adjustment [23]. Criteria for significance and relevance were an
FDR #0.05 and a log2 fold expression change of $0.5 (up-
regulation) or #0.5 (down-regulation), respectively.
Results
Enrollment, Retention, and Participant Disposition
A total of 65 participants were enrolled and randomized in the
study (TFV, n=16; N-9, n=17; HEC, n=16; and No Rx, n=16)
(Figure 1). The majority of participants were white males (Table 1).
There is no statistical difference between arms in age distribution
(p-value 0.79, ANOVA test), in gender composition (p-value 0.75,
Fisher’s exact test), nor in the proportion of white participants (p-
value 0.54, Chi-square test). One participant in the N-9 arm
withdrew from further participation after the enrollment visit
(before receiving any study product), due to an unrelated adverse
event. After completing their single-dose exposure, two partici-
pants did not receive products for the 7-day exposure. One
participant in the HEC group had major depression, was placed
on product hold, and was subsequently removed from the study.
The other participant in the TFV arm missed the Treatment Visit
2. Averaged across all study visits, the proportion of participants
who completed expected visits was 95% or above for all four study
arms.
Adherence and Acceptability
Among 46 participants who received products for the 7-day use
of gel, two participants had at least one product hold but later
resumed product use; one was due to moderate elbow cellulitis
after the Treatment visit 1 (N-9) and the other was due to
prohibited medication. Accounting for these product holds, only 1
participant in the N-9 arm reported using less than 80% of the
assigned doses between the Treatment Visit 2 and Final visit
(Table S2). Among 46 participants who were assigned to use gel
and completed the acceptability question, reported likelihood of
future product use (acceptability) was 93% (HEC), 87% (TFV,
Fisher exact test p-value = 1.0 when compared to the HEC group),
and 63% (N-9, Fisher exact test p-value = 0.08 when compared to
the HEC group).
Adverse Events
Adverse events were generally mild (Grade 1, N=121, 80% of
all AEs) or moderate (Grade 2, N= 27, 18% of all AEs). Two
Grade 3 events occurred in the No Rx arm and one Grade 4
psychiatric event (the major depression episode mentioned above)
occurred in the HEC arm prior to 7-day product use; all Grade 3
and 4 AEs were unrelated to product. Gastrointestinal adverse
events were common but the vast majority were mild (Table 2).
There were no significant differences in the proportion of
participants with $ Grade 2 or higher adverse events across the
arms of the study: 3/16 (19%) in the TFV arm, 7/17 (41%) in the
N-9 arm, 5/16 (31%) in the HEC arm, and 6/16 (38%) in the No
Rx arm; when compared to the No Rx arm, one sided Fisher exact
test yielded p-value 0.94 for the TFV arm, 0.56 for the N-9 arm,
and 0.77 for the HEC arm.
Mucosal Safety
Histology, fecal calprotectin, and epithelial
sloughing. There was suggestive evidence of increase in the
histology scores for the N-9 and HEC arms compared to the TFV
arm at the 9 cm site at the Final Visit (Table 3). In contrast, there
were no significant differences between the fecal calprotectin levels
or epithelial sloughing scores (data not shown).
Rectal microflora. There were no significant changes in
rectal microflora between the Baseline and Final Visits in any of
the gel arms (data not shown).
Mucosal T cell phenotype, cytokine and chemokine
mRNA expression, and Luminex analysis of rectal
secretions. Forty-five participants who completed more than
5 doses during the 7-day product use period as well as fifteen
Figure 1. Flow diagram of participant progress through the MTN-007 study.
doi:10.1371/journal.pone.0060147.g001
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participants in the No Rx arm who completed the Final Clinic
Visit were included in these biomarker analyses. Table 3 shows
biomarkers that have pairwise comparison nominal p-values less
than 0.05. Only two tests remain significant after Bonferroni
multiple testing correction (the comparisons of N-9 versus TFV for
IL-6 and IL-8 gene expression after the single-dose treatment).
Eight more comparisons meet the more lenient false discovery rate
cut-off 0.1 using the Benjamini-Hochberg procedure. The
Table 1. Baseline demographics of each treatment group.
All Arms Tenofovir Gel N-9 Gel HEC Placebo Gel No Treatment
Participants Enrolled 65 16 17 16 16
Age (Years) Mean (STD) 35.7 (11.0) 35.3 (8.7) 37.0 (9.9) 36.8 (12.6) 33.5 (13.0)
p-value 0.79
Gender Male 45 (69%) 10 (63%) 13 (76%) 12 (75%) 10 (63%)
Female 20 (31%) 6 (38%) 4 (24%) 4 (25%) 6 (38%)
p-value 0.75
Race White 44 (68%) 10 (63%) 13 (76%) 9 (56%) 12 (75%)
Non-white 21 (32%) 6 (37%) 4 (24%) 7 (44%) 4 (25%)
p-value 0.54
HEC, hydroxyethyl cellulose; N-9, Nonoxynol-9.
doi:10.1371/journal.pone.0060147.t001
Table 2. Participants reporting adverse events by study arm.
All Arms Tenofovir Gel N-9 Gel HEC Placebo Gel No Treatment
Participants enrolled 65 16 17 16 16
Total number of AEs 151 32 51 34 34
Grade 1 (Mild) 121 (80.1%) 29 (90.6%) 44 (86.3%) 26 (76.5%) 22 (64.7%)
Grade 2 (Moderate) 27 (17.9%) 3 (9.4%) 7 (13.7%) 7 (20.6%) 10 (29.4%)
Grade 3 (Severe) 2 (1.3%) 0 0 0 2 (5.9%)
Grade 4 (Potentially life-threatening)* 1 (0.7%) 0 0 1 (2.9%) 0
Grade 5 (Death) 0 0 0 0 0
Participants with one or more AEs
Grade 1 (Mild) 30 (46.2%) 7 (43.8%) 10 (58.8%) 7 (43.8%) 6 (37.5%)
Grade 2 (Moderate) 18 (27.7%) 3 (18.8%) 7 (41.2%) 4 (25.0%) 4 (25.0%)
Grade 3 (Severe) 2 (3.1%) 0 0 0 2 (12.5%)
Grade 4 (Potentially life-threatening) 1 (1.5%) 0 0 1 (6.3%) 0
Grade 5 (Death) 0 0 0 0 0
Participants with gastrointestinal AEs
Abdominal distension (G1/G2) 5 (7.7%) 1 (6.3%) 2 (11.8%) 2 (12.5%) 0
Abdominal pain (G1) 3 (4.6%) 1 (6.3%) 0 1 (6.3%) 1 (6.3%)
Anal pruritus (G1) 3 (4.6%) 1 (6.3%) 1 (5.9%) 1 (6.3%) 0
Defecation urgency (G1) 6 (9.2%) 0 5 (29.4%) 1 (6.3%) 0
Diarrhea (G1/G2/G3**) 9 (13.8%) 1 (6.3%) 4 (23.5%) 1 (6.3%) 3 (18.8%)
Flatulence (G1/G2) 13 (20%) 6 (37.5%) 2 (11.8%) 2 (12.5%) 3 (18.8%)
Haematochezia (G1) 1 (1.5%) 0 0 1 (6.3%) 0
Haemorrhoids (G1) 2 (3.1%) 0 1 (5.9%) 1 (6.3%) 0
Intestinal polyp (G1) 1 (1.5%) 0 0 0 1 (6.3%)
Painful defecation (G1) 2 (3.1%) 0 2 (11.8%) 0 0
Proctalgia (G1) 3 (4.6%) 1 (6.3%) 2 (11.8%) 0 0
Proctitis (G1) 1 (1.5%) 0 1 (5.9%) 0 0
Rectal polyp (G1) 3 (4.6%) 1 (6.3%) 1 (5.9%) 0 1 (6.3%)
HEC, hydroxyethyl cellulose; N-9, Nonoxynol-9; AEs, adverse events, *Grade 4 event was a participant who experienced a psychiatric AE (major depression) that occurred
prior to 7-day product use **Grade 3 diarrhea occurred in 1 participant in the No Treatment arm.
doi:10.1371/journal.pone.0060147.t002
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Table 3. Mucosal immunology assays with suggestive evidence of changes with nominal pairwise comparison p-value less than
0.05.
Tenofovir
Gel (T)
N-9 Gel
(N9)
HEC Placebo
Gel (H)
No Treatment
(N) p-Value
Participants analyzed 15 15 15 15
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Histology score
at 9 cm
Enrollment 0.7 (0.5) 1.0 (0.0) 1.1 (0.6) 0.9 (0.4)
Treatment 1 1.1 (0.6) 1.1 (0.7) 1.4 (0.8) 1.5 (1.0)
Final visit 0.7 (0.5) 1.8 (1.2) 1.1 (0.6) 1.4 (0.6) T:N9, 0.01, N9:H, 0.03
Flow cytometry
at 9 cm
Final Visit
CD45/CD3 (%) 51.7 (19.3) 48.5 (17.4) 41.0 (15.9) 57.7 (14.8) N9:H, 5.723
CD3/CD4 (%) 60.5 (9.0) 60.5 (7.9) 53.8 (10.8) 50.1 (11.1) N9:H, 0.04; N9:N, 0.01
CD4/CXCR4 (%) 48.0 (20.4) 59.6 (20.8) 49.4 (25.6) 38.2 (25.7) N9:N, 0.02
CD3/CD8 (%) 27.4 (8.6) 27.5 (7.6) 31.2 (8.6) 37.3 (10.4) N9:N, 1.623ˆ
CD8/CD69 (%) 71.3 (14.1) 69.5 (8.8) 75.0 (12.8) 83.4 (9.8) N9:N, 0.02
Flow cytometry
at 15 cm
Treatment 1
CD8/CD69 (%) 81.8 (9.1) 80.5 (14.3) 82.5 (11.5) 89.0 (5.4) T:N, 0.02
Final visit
CD45/CD3 (%) 57.3 (10.6) 47.2 (16.0) 42.8 (15.5) 50.8 (18.9) T:H, 0.04
CD3/CD8 (%) 31.2 (8.5) 32.8 (10.8) 30.3 (8.7) 36.5 (12.8) N9:N, 0.04
CD8/CCR5 (%) 90.0 (6.0) 84.7 (8.7) 80.3 (15.4) 80.8 (10.7) T:N, 0.01
qRT-PCR+ at 9 cm
Treatment 1
IL-1b 22.9 (0.6) 22.2 (0.8) 22.9 (0.8) 23.2 (0.6) N9:H, 6.824ˆ; N9:N,1.323ˆ
IL-6 24.2 (0.7) 23.1 (0.6) 24.0 (0.8) 24.3 (1.1) N9:T, 1.325*ˆ; N9:H, 3.024ˆ; N9:N,
4.323
TNF-a 23.3 (0.9) 22.8 (0.7) 23.5 (0.9) 23.8 (0.5) N9:H, 0.01; N9:N, 2.823
IL-8 23.0 (0.7) 22.1 (0.9) 23.0 (0.8) 23.2 (0.7) N9:T, 4.225*ˆ; N9:H, 2.824ˆ; N9:N,
4.923
MIP-1a 23.4 (0.7) 22.8 (0.7) 23.5 (0.8) 23.7 (0.6) N9:T, 2.724ˆ; N9:H, 2.523; N9:N,
2.623
MIP-1b 22.9 (0.8) 22.5 (0.7) 23.0 (0.8) 23.3 (0.5) N9:T, 1.823ˆ; N9:H, 7.423; N9:N,
8.023
IL-12p40 24.9 (0.8) 24.4 (0.8) 25.0 (1.0) 25.2 (0.7) N9:N, 0.02
IL-23 24.4 (1.1) 23.6 (1.0) 23.9 (0.7) 24.6 (0.9) N9:H, 0.02; N9:N, 0.01
CCR5 24.6 (0.8) 23.9 (0.6) 24.1 (0.6) 24.6 (0.7) N9:H, 0.03; N9:N, 6.023
Final visit
RANTES 22.7 (0.9) 22.5 (0.8) 22.4 (0.5) 22.6 (0.7) N9:T, 0.02; N9:H, 0.03; N9:N, 0.02
IL-17 24.9 (1.0) 24.4 (0.8) 24.5 (0.6) 24.9 (0.8) T:N, 0.02
qRT-PCR+ at 15 cm
Treatment 1
IFN-c 24.6 (0.6) 24.4 (0.8) 24.3 (0.6) 24.7 (0.4) N9:H, 0.04; N9:N, 0.04
RANTES 22.5 (0.9) 22.1 (0.7) 22.2 (0.6) 22.5 (0.6) T:N, 0.01
IL-17 24.8 (0.9) 24.4 (0.9) 24.4 (0.8) 25.2 (0.5) H:N, 0.02
Final visit
IL-6 24.5 (0.7) 24.3 (0.7) 24.0 (0.5) 24.5 (0.7) N9:H, 0.02
MIP-1a 23.4 (0.7) 23.6 (0.7) 23.6 (0.6) 23.9 (0.6) T:N, 0.04
RANTES 22.6 (1.0) 22.2 (0.7) 22.3 (0.5) 22.5 (0.7) N9:T, 0.01
IL-12p40 25.2 (0.9) 24.8 (1.1) 24.9 (0.7) 25.2 (0.6) T:H, 6.323; N9:H, 0.04
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majority of these changes involved upregulation of cytokine/
chemokine expression in the N-9 arm.
Microarray analysis. A single application of N-9 or TFV
up-regulated 24 genes and 70 genes, and down-regulated 30 and 8
genes, respectively. At the Final Visit, N-9 up-regulated 60 and
down-regulated 56 genes, whereas TFV up-regulated 137 and
down-regulated 505 genes (Figure 2). Background fluctuations in
the HEC and no-treatment arms were negligible (manuscript in
preparation).
Gender Specific and Regional Variations in Mucosal
Biomarkers
MTN-007 enrolled 20 women (31% of the study population) all
of whom reported RAI. Suggestive differences in T cell phenotype
(CD8+/CD69+) and mucosal cytokine/chemokine gene expres-
sion (TNF-a and IL-23) were also present when the data were
stratified by gender (manuscript in preparation). Regional
differences were seen in T cell phenotype (CD3+/CD8+,
CD8+/CD69+, CD4+/CD69+, CD4+/CXCR4+) and mucosal
cytokine/chemokine gene expression (IL-1b, IL-6, IL-8, MIP-1a,
MIP-1b, RANTES, IL-12p40, IL-17, and IL-23) between samples
collected at 9 cm and 15 cm (manuscript in preparation).
Discussion
This study demonstrates that the RG formulation of TFV gel is
safe and acceptable when administered for up to seven days in
sexually abstinent participants with a history of RAI. Gastrointes-
tinal AEs such as abdominal pain, rectal urgency, diarrhea, and
flatulence were the most common AEs seen but generally mild or
moderate. The preparatory enema and subsequent flexible
sigmoidoscopy may have contributed to these symptoms. Howev-
er, the overall rates of these symptoms were less than those seen in
the RMP-02/MTN-006 study which evaluated a more hyperos-
molar formulation of TFV gel [8]. Use of TFV gel did not appear
to be associated with mucosal damage as assessed by a broad range
of histological, immunological, and microbiological parameters.
Significant changes in gene expression were identified in the TFV
gel arm using microarray technology. The biological significance
of these changes, and more importantly whether they represent a
mucosal safety signal, is not clear and will require further
evaluation. A recent preclinical study identified intestinal injury
associated with in vitro exposure of colorectal explants to the
hyperosmolar vaginal formulation of TFV [9]. However, similar
histopathological changes were not seen in the TFV gel arm of the
MTN-007 study.
The inclusion of N-9 as a positive control was associated with
evidence of mild mucosal injury but was not associated with
significant changes in epithelial sloughing. Indeed epithelial
sloughing was seen at baseline in several participants. Non-human
primate studies of rectal exposure to N-9 also failed to demonstrate
epithelial sloughing [24]. Fecal calprotectin was also not elevated
Figure 2. Number of genes in rectal biopsies (9 cm) with
significant expression changes between baseline and after 7
days of treatment. The four ellipses represent each of the four
treatment arms, Nonoxynol 9 (N-9) gel, tenofovir (TFV) gel, hydro-
xyethylcellulose (HEC) gel or no gel (No Rx). The numbers of genes
changing expression exclusively in one study arm are indicated in fields
of the diagram that do not overlap with another field (N-9, 93 genes;
TFV, 608 genes; HEC, 11 genes; No Rx 12 genes). When identical genes
changed in more than one treatment arm, their number is placed into
the respective overlapping fields of the diagram. Choice of colors is
arbitrary to help visually distinguish each separate field of the diagram.
cRNA preparation, gene chip hybridization, and data significance
analysis was carried out as described in the Materials and Methods
section of the paper.
doi:10.1371/journal.pone.0060147.g002
Table 3. Cont.
Tenofovir
Gel (T)
N-9 Gel
(N9)
HEC Placebo
Gel (H)
No Treatment
(N) p-Value
IL-23 24.5 (1.1) 24.0 (1.1) 23.9 (0.7) 24.7 (1.0) H:N, 7.523
Luminex assay
Treatment 1
IL-8 164.3 (229.9) 537.3 (421.9) 510.9 (570.9) 303.5 (498.4) N9:T, 0.02
MIP-1a 2.6 (1.1) 4.1 (3.1) 5.0 (5.2) 7.2 (7.7) T:N, 0.03
RANTES 8.3 (10.1) 335.9 (429.1) 12.1 (10.6) 33.1 (74.6) N9:T, 3.623; N9:H, 1.323ˆ; N9:N,
0.01
Final visit
TNF-a 3.0 (4.0) 2.2 (1.9) 2.7 (2.1) 1.4 (1.0) H:N, 0.04
HEC, hydroxyethyl cellulose; N-9, Nonoxynol-9, qRT-PCR, quantitative reverse transcriptase PCR, RANTES; Regulated upon activation normal T cell expressed.
+Data expressed as logarithm (base 10) transformation of the number of copies of gene of interest/the number of copies of b2 microglobulin in the same sample.
*p-values that are significant after controlling for family-wise error rate at 0.05 using Bonferroni correction.
pˆ-values that are significant after controlling for false discovery rate at 0.1 using the Benjamini-Hochberg procedure.
doi:10.1371/journal.pone.0060147.t003
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throughout the study. This assay is useful in discriminating
between irritable bowel syndrome and IBD [19] but appears to
have limited utility in the evaluation of RM. Based on these data,
the MTN will not use these two assays in future Phase 1/2 studies
of candidate RM.
It is unclear whether the changes in mucosal gene expression
assessed by microarray are related to the TFV or its associated
formulation. Future RM studies may answer this question. The
CHARM-01 study (NCT01575405) will explore the impact of
three different TFV formulations on rectal safety and acceptabil-
ity. Each formulation has a different osmolality ranging from 479
to 3111 mOsmol/kg) and the study should be able to evaluate the
impact of osmolality on mucosal safety. The MTN-017 study
(NCT01687218) will be a Phase-2 RM study in which participants
will receive 8 weeks of TFV gel (either daily or with sex) followed
by 8 weeks of oral TruvadaH. This study will provide information
on the consequences of extended exposure to rectal TFV as well as
a crossover comparison of oral and topical exposure to TFV. Both
studies are expected to start in 2013.
Importantly, 31% of the participants in MTN-007 were women;
emphasizing the need for RM for both men and women. We
observed some modest gender specific differences in mucosal
safety biomarkers but a larger study would be required to provide
more definitive data on the impact of gender on the gastrointes-
tinal mucosa. Differences in mucosal safety parameters between
the 9 cm and 15 cm samples were more marked and in keeping
with previous studies demonstrating regional heterogeneity in
colonic mucosal biology [18,25].
This study demonstrated that it is possible to collect adequate
mucosal samples for Phase 1 RM studies via anoscopy. This
observation will potentially simplify the design and execution of
future Phase 1 RM studies although it is difficult to collect more
than 7 rectal biopsies via anoscopy and so studies requiring
collection of rectal samples for mucosal safety, pharmacokinetic,
and pharmacodynamic assessment may still require flexible
sigmoidoscopy.
It is encouraging that the RG formulation of TFV is well
tolerated as the vaginal formulation used in previous studies was
associated with a high frequency of gastrointestinal side effects
when given rectally [8]. This safety profile together with evidence
from the RMP-02/MTN-006 study showing that rectal use of
TFV is associated with ex vivo/in vitro inhibition of HIV-1 viral
replication [8] provides a compelling rationale for progression of
this product into Phase 2 development. Collectively, these data will
determine the longer term safety profile of this product and help
decide whether it is a suitable agent to take into Phase 3
effectiveness studies.
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